Published in Neoplasia on February 01, 2009
Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer (2014) 2.00
Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci (2012) 1.23
Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. Neoplasia (2009) 1.22
Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol (2012) 1.18
Molecular networks implicated in speech-related disorders: FOXP2 regulates the SRPX2/uPAR complex. Hum Mol Genet (2010) 1.17
Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol (2013) 1.09
Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation. Neoplasia (2010) 1.03
Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol (2012) 1.02
Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev (2012) 0.92
Expression characteristics of hypoxia-inducible factor-1α and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon (2011) 0.91
PLAUR polymorphisms and lung function in UK smokers. BMC Med Genet (2009) 0.91
A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia (2009) 0.91
Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway. Nucleic Acids Res (2011) 0.86
STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases. Neoplasia (2012) 0.85
The impact of hypoxia on tumor-associated macrophages. J Clin Invest (2016) 0.77
Genome-wide analysis in human colorectal cancer cells reveals ischemia-mediated expression of motility genes via DNA hypomethylation. PLoS One (2014) 0.76
The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) (2014) 0.76
The interconnectedness of cancer cell signaling. Neoplasia (2011) 0.75
Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. Cancer Lett (2016) 0.75
The War on Cancer rages on. Neoplasia (2009) 0.75
Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator. Exp Biol Med (Maywood) (2014) 0.75
Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia (2010) 0.75
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix. Int J Clin Oncol (2014) 0.75
Hypoxia and Bone Metastatic Disease. Curr Osteoporos Rep (2017) 0.75
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 22.06
A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64
Integrin signaling. Science (1999) 16.44
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (1996) 10.14
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst (2001) 8.57
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem (1997) 7.67
Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem (1996) 7.37
Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev (2007) 6.91
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 6.86
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31
uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol (2002) 6.24
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res (1998) 5.86
Cloning of a factor required for activity of the Ah (dioxin) receptor. Science (1991) 5.84
Integration of oxygen signaling at the consensus HRE. Sci STKE (2005) 4.95
Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science (1992) 4.70
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem (1996) 3.80
Regulation of integrin function by the urokinase receptor. Science (1996) 3.56
Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell (1998) 2.75
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A (1985) 2.72
Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res (2003) 2.66
Genetic progression in the pancreatic ducts. Am J Pathol (2000) 2.58
Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst (2001) 2.44
The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem (1996) 2.30
'The metabolism of tumours': 70 years later. Novartis Found Symp (2001) 1.99
Candidate genes for the hypoxic tumor phenotype. Cancer Res (2000) 1.94
Causes and effects of heterogeneous perfusion in tumors. Neoplasia (1999) 1.76
The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res (2006) 1.75
High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia (2008) 1.56
Genetic progression and divergence in pancreatic carcinoma. Am J Pathol (2000) 1.53
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
HIF hydroxylation and cellular oxygen sensing. Biol Chem (2004) 1.32
Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia (2008) 1.23
The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer (2006) 1.20
Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia (2003) 1.15
Regulation, initiation, and termination of the cenA and cex transcripts of Cellulomonas fimi. J Bacteriol (1987) 1.14
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol (1998) 1.12
Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol Pathol (1999) 1.11
Activation of the Sap-1a transcription factor by the c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase. J Biol Chem (1997) 1.10
Disruption of dimerization and substrate phosphorylation inhibit factor inhibiting hypoxia-inducible factor (FIH) activity. Biochem J (2004) 1.08
Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood (2002) 1.06
Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol (2006) 1.05
Tumor hypoxia, drug resistance, and metastases. J Natl Cancer Inst (1990) 1.00
Tumor cell intravasation alu-cidated: the chick embryo opens the window. Cell (1998) 1.00
Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol (2007) 0.99
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. Neoplasia (2008) 0.97
Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. Pancreas (2003) 0.97
Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia (2007) 0.96
Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arterioscler Thromb Vasc Biol (2000) 0.95
The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiation. J Neurosci (2000) 0.93
A conserved TATA-less proximal promoter drives basal transcription from the urokinase-type plasminogen activator receptor gene. Blood (1995) 0.93
A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia (2005) 0.90
The hypoxia-inducible factor-1 DNA recognition site is cAMP-responsive. Kidney Int (1997) 0.88
uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. Cell Res (2006) 0.81
Antiangiogenic therapy and p53. Science (2002) 0.80
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med (2010) 4.13
Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res (2008) 3.17
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg (2003) 3.12
Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg (2011) 2.92
Most pancreatic cancer resections are R1 resections. Ann Surg Oncol (2008) 2.79
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol (2012) 2.59
Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg (2007) 2.51
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res (2003) 2.27
Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg (2008) 2.22
Readmissions following pancreaticoduodenectomy for pancreas cancer: a population-based appraisal. Ann Surg Oncol (2008) 2.20
Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology (2007) 2.15
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol (2008) 2.05
Pancreatic-pleural fistula is best managed by early operative intervention. Surgery (2009) 2.03
Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther (2008) 1.95
Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg (2008) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Pouch vs. no pouch following total gastrectomy: meta-analysis and systematic review. Am J Gastroenterol (2009) 1.88
Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg (2007) 1.85
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol (2008) 1.82
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res (2006) 1.82
Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol (2010) 1.82
From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A (2009) 1.75
European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis (2013) 1.75
Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment. Clin Cancer Res (2005) 1.74
Combined laparoscopic-endoscopic resections of colorectal polyps: 10-year experience and follow-up. Surg Endosc (2009) 1.74
Pancreatic cancer microenvironment. Int J Cancer (2007) 1.73
Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg (2008) 1.73
Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy (2011) 1.73
Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol (2011) 1.72
Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. Gastrointest Endosc (2004) 1.70
Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. Gastroenterology (2008) 1.68
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene (2005) 1.67
Telomerase gene mutations are associated with cirrhosis formation. Hepatology (2011) 1.67
Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Cancer (2007) 1.63
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology (2013) 1.62
Invasion and metastasis in pancreatic cancer. Mol Cancer (2003) 1.61
Pancreaticojejunostomy versus pancreaticogastrostomy: systematic review and meta-analysis. Am J Surg (2007) 1.60
Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg (2011) 1.59
Recruitment of the NCoA/SRC-1/p160 family of transcriptional coactivators by the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator complex. Mol Cell Biol (2002) 1.58
Laparoscopic surgery for cancer: a systematic review and a way forward. J Am Coll Surg (2010) 1.58
Renal cancer cell metastasis into the pancreas: a single-center experience and overview of the literature. Pancreas (2005) 1.58
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem (2006) 1.58
CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer (2010) 1.56
Controversies in clinical pancreatology: management of acute idiopathic recurrent pancreatitis. Pancreas (2003) 1.56
Duodenum-preserving pancreatic head resection--a randomized controlled trial comparing the original Beger procedure with the Berne modification (ISRCTN No. 50638764). Surgery (2008) 1.55
Complications of pancreatic surgery. HPB (Oxford) (2005) 1.54
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg (2013) 1.53
Is there still a role for total pancreatectomy? Ann Surg (2007) 1.52
Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res (2007) 1.52
Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia (2009) 1.52
Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer (2005) 1.51
Management of early hemorrhage from pancreatic anastomoses after pancreaticoduodenectomy. Dig Surg (2006) 1.51
Pancreatic cancer: from bench to 5-year survival. Pancreas (2006) 1.49
Neurokinin-2 receptor levels correlate with intensity, frequency, and duration of pain in chronic pancreatitis. Ann Surg (2007) 1.48
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. J Gastrointest Surg (2009) 1.47
Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol (2008) 1.47
Management of pain in small duct chronic pancreatitis. J Gastrointest Surg (2006) 1.47
Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients. Arch Surg (2005) 1.47
Carcinoid of the ampulla of Vater. J Gastroenterol Hepatol (2005) 1.44
Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg (2007) 1.44
Are 12 nodes needed to accurately stage T1 and T2 colon cancers? Dig Dis Sci (2008) 1.44
Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. Am J Pathol (2002) 1.42
Extended Ischemia Times Promote Risk of HCC Recurrence in Liver Transplant Patients. Dig Dis Sci (2015) 1.42
Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg (2007) 1.41
Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett (2006) 1.41
Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett (2008) 1.41
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res (2010) 1.40
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer (2003) 1.39
Desmoplastic reaction influences pancreatic cancer growth behavior. World J Surg (2004) 1.39
Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer (2002) 1.39
Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology (2002) 1.38
Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res (2005) 1.38
Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg (2006) 1.38
Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg (2005) 1.38
Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol (2006) 1.38
Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol (2005) 1.37
Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg (2006) 1.36
Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg (2007) 1.34
Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. Am J Physiol Gastrointest Liver Physiol (2005) 1.33